{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:30:31Z","timestamp":1781796631578,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Joint Co-construction Project of Henan Medical Science and Technology Research Plan","award":["LHGJ20190740"],"award-info":[{"award-number":["LHGJ20190740"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Targeted therapies have markedly improved the prognosis of lung cancer patients; nevertheless, challenges persist, including limited beneficiary populations and the emergence of drug resistance. This study investigates the molecular mechanisms of mutant TP53 in lung cancer, aiming to contribute to novel strategies for targeted therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The TCGA database was employed to delineate the mutational landscape of TP53 in lung cancer patients. Differential gene expression between TP53-mutant and wild-type patients was analyzed, followed by functional enrichment. DSG3 protein expression in lung cancer patients was assessed using IHC, and its impact on prognosis was analyzed in the TCGA database. The influence of TP53 on the downstream gene DSG3 was investigated using qPCR, ChIP-qPCR, and luciferase reporter gene assays. Protein enrichment in the DSG3 promoter region was examined through IP-MS, and the regulatory role of the HIF1-\u03b1\/TP53 complex on DSG3 was explored using Co-IP, luciferase assays, and ChIP-qPCR. Molecular interactions between TP53 (R273H) and HIF1-\u03b1 were detected through immunoprecipitation and molecular docking. The effects and mechanisms of DSG3 on lung cancer phenotypes were assessed through WB, transwell, and wound healing assays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>TP53 mutations were present in 47.44% of patients, predominantly as missense mutations. DSG3 exhibited high expression in TP53-mutant lung cancer patients, and this elevated expression correlated with a poorer prognosis. TP53 interference led to a reduction in DSG3 mRNA expression, with TP53 mutant P53 enriching at the P2 site of the DSG3 promoter region, a recruitment facilitated by HIF1-\u03b1. The DBD region of TP53 (R273H) demonstrated interaction with HIF1-\u03b1. DSG3, activated through Ezrin phosphorylation, played a role in promoting invasion and metastasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Mutant TP53 facilitates lung cancer cell invasion by modulating desmoglein 3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05778-3","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T05:02:06Z","timestamp":1718859726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3"],"prefix":"10.1007","volume":"150","author":[{"given":"Yu","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiang","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"5778_CR1","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/ncomms3667","volume":"4","author":"A Ali","year":"2013","unstructured":"Ali A, Wang Z, Fu J et al (2013) Differential regulation of the REG\u03b3-proteasome pathway by p53\/TGF-\u03b2 signalling and mutant p53 in cancer cells. Nat Commun 4:2667. https:\/\/doi.org\/10.1038\/ncomms3667. (PubMed PMID: 24157709)","journal-title":"Nat Commun"},{"issue":"46","key":"5778_CR2","doi-asserted-by":"publisher","first-page":"E10869","DOI":"10.1073\/pnas.1808314115","volume":"115","author":"I Amelio","year":"2018","unstructured":"Amelio I, Mancini M, Petrova V et al (2018) p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci USA 115(46):E10869\u2013E10878. https:\/\/doi.org\/10.1073\/pnas.1808314115. (PubMed PMID: 30381462)","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"5778_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188753","volume":"1877","author":"G Barik","year":"2022","unstructured":"Barik G, Sahay O, Paul D et al (2022) Ezrin gone rogue in cancer progression and metastasis: an enticing therapeutic target. Biochim Biophys Acta 1877(4):188753. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188753. (PubMed PMID: 35752404)","journal-title":"Biochim Biophys Acta"},{"key":"5778_CR4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210418120","author":"M Benjamin","year":"2023","unstructured":"Benjamin M, Jacob PH, Christian GC-S et al (2023) ABL kinases regulate the stabilization of HIF-1\u03b1 and MYC through\u00a0CPSF1. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2210418120. (PubMed PMID: 37040401)","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5778_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12935-020-01472-9","volume":"20","author":"F Bi","year":"2020","unstructured":"Bi F, Chen Y, Yang Q (2020) Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. Cancer Cell Int 20:373. https:\/\/doi.org\/10.1186\/s12935-020-01472-9. (PubMed PMID: 32774167)","journal-title":"Cancer Cell Int"},{"issue":"12","key":"5778_CR6","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/pro.2172","volume":"21","author":"R Cardoso","year":"2012","unstructured":"Cardoso R, Love R, Nilsson C et al (2012) Identification of Cys255 in HIF-1\u03b1 as a novel site for development of covalent inhibitors of HIF-1\u03b1\/ARNT PasB domain protein-protein interaction. Protein Sci 21(12):1885\u20131896. https:\/\/doi.org\/10.1002\/pro.2172. (PubMed PMID: 23033253)","journal-title":"Protein Sci"},{"issue":"7511","key":"5778_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543\u2013550. https:\/\/doi.org\/10.1038\/nature13385. (PubMed PMID: 25079552)","journal-title":"Nature"},{"issue":"8","key":"5778_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina J (2019) Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 94(8):1623\u20131640. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.013. (PubMed PMID: 31378236)","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"5778_CR9","doi-asserted-by":"publisher","first-page":"8748","DOI":"10.1093\/nar\/gkt630","volume":"41","author":"A Eldar","year":"2013","unstructured":"Eldar A, Rozenberg H, Diskin-Posner Y et al (2013) Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions. Nucleic Acids Res 41(18):8748\u20138759. https:\/\/doi.org\/10.1093\/nar\/gkt630. (PubMed PMID: 23863845)","journal-title":"Nucleic Acids Res"},{"key":"5778_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154200","author":"V Florian","year":"2022","unstructured":"Florian V, Ahmad A, Natalia G et al (2022) Desmoglein 3 (Dsg3) expression in cancer: a tissue microarray study on 15,869 tumors. Pathol Res Pract. https:\/\/doi.org\/10.1016\/j.prp.2022.154200. (PubMed PMID: 36375372)","journal-title":"Pathol Res Pract"},{"issue":"12","key":"5778_CR11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"W Freed-Pastor","year":"2012","unstructured":"Freed-Pastor W, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26(12):1268\u20131286. https:\/\/doi.org\/10.1101\/gad.190678.112. (PubMed PMID: 22713868)","journal-title":"Genes Dev"},{"key":"5778_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","volume":"148","author":"W Freed-Pastor","year":"2012","unstructured":"Freed-Pastor W, Mizuno H, Zhao X et al (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148:244\u2013258. https:\/\/doi.org\/10.1016\/j.cell.2011.12.017. (PubMed PMID: 22265415)","journal-title":"Cell"},{"issue":"1","key":"5778_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1021\/ci300425v","volume":"53","author":"P Greenidge","year":"2013","unstructured":"Greenidge P, Kramer C, Mozziconacci J et al (2013) MM\/GBSA binding energy prediction on the PDBbind data set: successes, failures, and directions for further improvement. J Chem Inf Model 53(1):201\u2013209. https:\/\/doi.org\/10.1021\/ci300425v. (PubMed PMID: 23268595)","journal-title":"J Chem Inf Model"},{"issue":"1","key":"5778_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu J, Cao J, Topatana W et al (2021) Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol 14(1):157. https:\/\/doi.org\/10.1186\/s13045-021-01169-0. (PubMed PMID: 34583722)","journal-title":"J Hematol Oncol"},{"issue":"30","key":"5778_CR15","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.2174\/1381612824666180926095709","volume":"24","author":"R Kaur","year":"2018","unstructured":"Kaur R, Vasudeva K, Kumar R et al (2018) Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies. Curr Pharm Des 24(30):3566\u20133575. https:\/\/doi.org\/10.2174\/1381612824666180926095709. (PubMed PMID: 30255744)","journal-title":"Curr Pharm Des"},{"issue":"5","key":"5778_CR16","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41418-022-00989-y","volume":"29","author":"M Kennedy","year":"2022","unstructured":"Kennedy M, Lowe S (2022) Mutant p53: it\u2019s not all one and the same. Cell Death Differ 29(5):983\u2013987. https:\/\/doi.org\/10.1038\/s41418-022-00989-y. (PubMed PMID: 35361963)","journal-title":"Cell Death Differ"},{"key":"5778_CR17","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/ncomms8389","volume":"6","author":"M Kollareddy","year":"2015","unstructured":"Kollareddy M, Dimitrova E, Vallabhaneni K et al (2015) Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat Commun 6:7389. https:\/\/doi.org\/10.1038\/ncomms8389. (PubMed PMID: 26067754)","journal-title":"Nat Commun"},{"issue":"1","key":"5778_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar P et al (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 22(1):40. https:\/\/doi.org\/10.1186\/s12943-023-01740-y. (PubMed PMID: 36810079)","journal-title":"Mol Cancer"},{"issue":"7","key":"5778_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41416-019-0383-z","volume":"120","author":"N Li","year":"2019","unstructured":"Li N, Kong J, Lin Z et al (2019) Ezrin promotes breast cancer progression by modulating AKT signals. Br J Cancer 120(7):703\u2013713. https:\/\/doi.org\/10.1038\/s41416-019-0383-z. (PubMed PMID: 30804430)","journal-title":"Br J Cancer"},{"key":"5778_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7010266","author":"B Louise","year":"2015","unstructured":"Louise B, Hong W (2015) Desmoglein 3: a help or a hindrance in cancer progression? Cancers (basel). https:\/\/doi.org\/10.3390\/cancers7010266. (PubMed PMID: 25629808)","journal-title":"Cancers (basel)."},{"issue":"1","key":"5778_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12862-023-02146-6","volume":"23","author":"M Mansur","year":"2023","unstructured":"Mansur M, Greaves M (2023) Convergent TP53 loss and evolvability in cancer. BMC Ecol Evol 23(1):54. https:\/\/doi.org\/10.1186\/s12862-023-02146-6. (PubMed PMID: 37743495)","journal-title":"BMC Ecol Evol"},{"issue":"2","key":"5778_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G (2019) Mutant p53 as a guardian of the cancer cell. Cell Death Differ 26(2):199\u2013212. https:\/\/doi.org\/10.1038\/s41418-018-0246-9. (PubMed PMID: 30538286)","journal-title":"Cell Death Differ"},{"issue":"6255","key":"5778_CR23","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1126\/science.aab4082","volume":"349","author":"I Martincorena","year":"2015","unstructured":"Martincorena I, Campbell P (2015) Somatic mutation in cancer and normal cells. Science (new York, NY) 349(6255):1483\u20131489. https:\/\/doi.org\/10.1126\/science.aab4082. (PubMed PMID: 26404825)","journal-title":"Science (new York, NY)"},{"issue":"11","key":"5778_CR24","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D, Assenov Y et al (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28(11):1747\u20131756. https:\/\/doi.org\/10.1101\/gr.239244.118. (PubMed PMID: 30341162)","journal-title":"Genome Res"},{"key":"5778_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145796","author":"R Mohsen","year":"2021","unstructured":"Mohsen R, Leila Rostami Z, Behzad B et al (2021) Up\u2013down regulation of HIF-1\u03b1 in cancer progression. Gene. https:\/\/doi.org\/10.1016\/j.gene.2021.145796. (PubMed PMID: 34175393)","journal-title":"Gene"},{"issue":"12","key":"5778_CR26","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1101\/gad.263202.115","volume":"29","author":"N Pfister","year":"2015","unstructured":"Pfister N, Fomin V, Regunath K et al (2015) Mutant p53 cooperates with the SWI\/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev 29(12):1298\u20131315. https:\/\/doi.org\/10.1101\/gad.263202.115. (PubMed PMID: 26080815)","journal-title":"Genes Dev"},{"issue":"12","key":"5778_CR27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/bioinformatics\/btu097","volume":"30","author":"B Pierce","year":"2014","unstructured":"Pierce B, Wiehe K, Hwang H et al (2014) ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics (oxf, Engl) 30(12):1771\u20131773. https:\/\/doi.org\/10.1093\/bioinformatics\/btu097. (PubMed PMID: 24532726)","journal-title":"Bioinformatics (oxf, Engl)"},{"issue":"8","key":"5778_CR28","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1080\/15548627.2019.1687213","volume":"16","author":"K Qureshi-Baig","year":"2020","unstructured":"Qureshi-Baig K, Kuhn D, Viry E et al (2020) Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC\/PKC-EZR (ezrin) pathway. Autophagy 16(8):1436\u20131452. https:\/\/doi.org\/10.1080\/15548627.2019.1687213. (PubMed PMID: 31775562)","journal-title":"Autophagy"},{"issue":"10","key":"5778_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41419-019-1988-0","volume":"10","author":"A Rehman","year":"2019","unstructured":"Rehman A, Cai Y, H\u00fcnefeld C et al (2019) The desmosomal cadherin desmoglein-3 acts as a keratinocyte anti-stress protein via suppression of p53. Cell Death Dis 10(10):750. https:\/\/doi.org\/10.1038\/s41419-019-1988-0. (PubMed PMID: 31582719)","journal-title":"Cell Death Dis"},{"key":"5778_CR30","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1242\/jcs.061002","volume":"123","author":"L Roger","year":"2010","unstructured":"Roger L, Jullien L, Gire V et al (2010) Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci 123:1295\u20131305. https:\/\/doi.org\/10.1242\/jcs.061002. (PubMed PMID: 20332115)","journal-title":"J Cell Sci"},{"issue":"2","key":"5778_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trecan.2020.01.007","volume":"6","author":"A Shahbandi","year":"2020","unstructured":"Shahbandi A, Nguyen H, Jackson J (2020) TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer 6(2):98\u2013110. https:\/\/doi.org\/10.1016\/j.trecan.2020.01.007. (PubMed PMID: 32061310)","journal-title":"Trends Cancer"},{"issue":"1","key":"5778_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/cdd.2017.174","volume":"25","author":"K Sullivan","year":"2018","unstructured":"Sullivan K, Galbraith M, Andrysik Z et al (2018) Mechanisms of transcriptional regulation by p53. Cell Death Differ 25(1):133\u2013143. https:\/\/doi.org\/10.1038\/cdd.2017.174. (PubMed PMID: 29125602)","journal-title":"Cell Death Differ"},{"issue":"5","key":"5778_CR33","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1053\/j.gastro.2020.07.046","volume":"159","author":"A Tiwari","year":"2020","unstructured":"Tiwari A, Tashiro K, Dixit A et al (2020) Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis. Gastroenterology 159(5):1882-1897.e5. https:\/\/doi.org\/10.1053\/j.gastro.2020.07.046. (PubMed PMID: 32768595)","journal-title":"Gastroenterology"},{"key":"5778_CR34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.217430","author":"G Valentina","year":"2019","unstructured":"Valentina G, Candida V, Maria T et al (2019) HIF-1\u03b1 is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.217430. (PubMed PMID: 31289209)","journal-title":"Haematologica"},{"key":"5778_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154200","volume":"240","author":"F Viehweger","year":"2022","unstructured":"Viehweger F, Azem A, Gorbokon N et al (2022) Desmoglein 3 (Dsg3) expression in cancer: a tissue microarray study on 15,869 tumors. Pathol Res Pract 240:154200. https:\/\/doi.org\/10.1016\/j.prp.2022.154200. (PubMed PMID: 36375372)","journal-title":"Pathol Res Pract"},{"issue":"3","key":"5778_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ijc.32133","volume":"145","author":"A Volckmar","year":"2019","unstructured":"Volckmar A, Leichsenring J, Kirchner M et al (2019) Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3000 Heidelberg cases. Int J Cancer 145(3):649\u2013661. https:\/\/doi.org\/10.1002\/ijc.32133. (PubMed PMID: 30653256)","journal-title":"Int J Cancer"},{"key":"5778_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fonc.2015.00289","volume":"5","author":"D Walerych","year":"2015","unstructured":"Walerych D, Lisek K, Del Sal G (2015) Mutant p53: one, no one, and one hundred thousand. Front Oncol 5:289. https:\/\/doi.org\/10.3389\/fonc.2015.00289. (PubMed PMID: 26734571)","journal-title":"Front Oncol"},{"issue":"5","key":"5778_CR38","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41418-022-00962-9","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang Z, Strasser A, Kelly G (2022) Should mutant TP53 be targeted for cancer therapy? Cell Death Differ 29(5):911\u2013920. https:\/\/doi.org\/10.1038\/s41418-022-00962-9. (PubMed PMID: 35332311)","journal-title":"Cell Death Differ"},{"issue":"3","key":"5778_CR39","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1158\/1535-7163.mct-06-0336","volume":"6","author":"R Wong","year":"2007","unstructured":"Wong R, Tsang W, Chau P et al (2007) p53\u2013R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther 6(3):1054\u20131061. https:\/\/doi.org\/10.1158\/1535-7163.mct-06-0336. (PubMed PMID: 17363498)","journal-title":"Mol Cancer Ther"},{"key":"5778_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010004","author":"S Yamamoto","year":"2018","unstructured":"Yamamoto S, Iwakuma T (2018) Regulators of oncogenic mutant TP53 gain of function. Cancers. https:\/\/doi.org\/10.3390\/cancers11010004. (PubMed PMID: 30577483)","journal-title":"Cancers"},{"issue":"5","key":"5778_CR41","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L, Han Y et al (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16(5):284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118. (PubMed PMID: 22455463)","journal-title":"OMICS"},{"key":"5778_CR42","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1038\/ncomms3935","volume":"4","author":"C Zhang","year":"2013","unstructured":"Zhang C, Liu J, Liang Y et al (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 4:2935. https:\/\/doi.org\/10.1038\/ncomms3935. (PubMed PMID: 24343302)","journal-title":"Nat Commun"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05778-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:54:24Z","timestamp":1720522464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05778-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["5778"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05778-3","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research was approved by the Ethics Committee of Henan Provincial Chest Hospital (NO. 2020-07-017). All animal research was carried out following Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"312"}}